Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application

Science China Life Sciences

Volumn 56, Issue 1, 2013, Pages 51-58

  Dai, ChuanYun ^a   Fu, Ya ^a   Chen, ShaoCheng ^b   Li, Biao ^c   Yao, Bo ^a   Liu, WanHong ^a   Zhu, LiQing ^a   Chen, Nan ^a   Chen, Ji ^a   Zhang, Qiang ^d  

^a CHONGQING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHONGQING UNIVERSITY OF EDUCATION   (China)

^c INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

anti tumor effect; dipeptide; releasable PEGylation; tumor necrosis factor

Indexed keywords

EID: 84872284972     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4431-7     Document Type: Article

References (31)

1. Chapman P B, Lester T J, Casper E S, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol, 1987, 5: 1942-1951.
2. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliver Rev, 2001, 46: 169-185.
3. Blick M, Sherwin S A, Rosenblum M, et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res, 1987, 47: 2986-2989.
4. Harris J M, Chess R B. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov, 2003, 2: 214-221.
5. Tsutsumi Y, Kihira T, Tsunoda S, et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer, 1995, 71: 963-968.
6. Tsutsumi Y, Kihira T, Yamamoto S, et al. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency. Jpn J Cancer Res, 1994, 85: 9-12.
7. Tsutsumi Y, Tsunoda S, Kamada H, et al. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. Br J Cancer, 1996, 74: 1090-1095.
8. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of PEGylated recombinant IFN-alpha2b. J Interferon Cytokine Res, 2001, 21: 1103-1115.
9. DeFrees S, Wang Z G, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology, 2006, 16: 833-843.
10. Shaunak S, Godwin A, Choi J W, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol, 2006, 2: 312-313.
11. Filpula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev, 2008, 60: 29-49.
12. Otto H H, Schirmeister T. Cysteine proteases and their inhibitors. Chem Rev, 1997, 97: 133-172.
13. Hashimoto Y, Kakegawa H, Narita Y, et al. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Bioph Res Commun, 2001, 283: 334-339.
14. Barrett A J, Kembhavi A A, Brown M A, et al. L-trans-epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J, 1982, 201: 189-198.
15. Kovar M, Strohalm J, Etrych T, et al. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem, 2002, 13: 206-215.
16. Studer M, Kroger L A, DeNardo S J, et al. Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymic digestion in vitro and in vivo. Bioconjug Chem, 1992, 3: 424-429.
17. Versluis A J, Rump E T, Rensen P C N, et al. Synthesis of a lipophilic daunoruhicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm Res, 1998, 15: 531-537.
18. Afar D E H, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther, 2004, 3: 921-932.
19. Francisco J A, Cerveny C G, Meyer D L, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 2003, 102: 1458-1465.
20. Sanderson R J, Hering M A, James S F, et al. In vivo Drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res, 2005, 11: 843-852.
21. Dai C Y, Fu Y, Li B, et al. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma. Sci China Life Sci, 2011, 54: 128-138.
22. Stocks S J, Jones A J M, Ramey C W, et al. A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem, 1986, 154: 232-234.
23. Yamazaki S, Onishi E, Enami K, et al. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol, 1986, 39: 105-118.
24. Kamada H, Tsutsumi Y, Tsunoda S, et al. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha. Biochem Biophys Res Commun, 1999, 257: 448-453.
25. Ishiyama M, Tominaga H, Shiga M, et al. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996, 19: 1518-1520.
26. Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer, 1984, 34: 263-267.
27. Carswell E A, Old L J, Kassel R L, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 1975, 72: 3666-3670.
28. Aniento F, Roche E, Cuervo A M, et al. Uptake and degradation of glyceraldehyde-3-phosphate dehydrogenase by rat liver lysosomes. J Biol Chem, 1993, 268: 10463-10470.
29. Murata M, Miyashita S, Yokoo C, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett, 1991, 280: 307-310.
30. Barrett A J, Kirschke H. Cathepsin B. Methods Enzymol, 1981, 80: 535-561.
31. Vasey P A, Kaye S B, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res, 1999, 5: 83-94.